Key result
Stentless bioprostheses for RVOT replacement after the Ross procedure had a higher incidence of reintervention compared to homografts.
Why the study?
Does RVOT replacement with stentless bioprostheses compared to homografts increase the risk of reintervention in adult patients undergoing the Ross procedure?
Cohort (n=186)
Does RVOT replacement with stentless bioprostheses compared to homografts increase the risk of reintervention in adult patients undergoing the Ross procedure?
Answers are grounded in this paper and cite their sources.
In adult patients undergoing the Ross procedure, RVOT replacement with stentless bioprostheses is associated with a significantly higher risk of reintervention and higher gradients compared to homografts.
OBJECTIVES: Although data from large series indicate the satisfactory performance of bioprosthetic valves in the right ventricular outflow tract (RVOT), replacement of the pulmonary valve in adult patients undergoing the Ross procedure is usually performed with pulmonary allografts. We evaluated the outcomes of homografts vs. bioprosthetic RVOT replacement after the Ross procedure in adults. METHODS: Between 1996 and 2011, a total of 186 adult patients (141 male; mean age 44 ± 10 years) underwent aortic root replacement with a pulmonary autograft. The RVOT was replaced with a homograft in 113 patients and with stentless bioprostheses (Medtronic Freestyle(®)) in 73. Patients were followed for a mean of 6 years (range 1-15 years; 1106 patient years). RESULTS: Twelve patients required reintervention owing to dysfunction of the RVOT replacement, which was caused by endocarditis (n = 4), degeneration (n = 2) or stricture at the proximal suture line (n = 6). For homografts, the incidence of reintervention was 1 in 150 patient years, compared with 1 in 36 patient years for stentless bioprostheses (P = 0.007). The median gradient was 15 mmHg for the homograft group and 24 mmHg for bioprosthesis (P < 0.0001). The incidence of gradients >40 mmHg was 10-fold higher in the bioprosthetic group. CONCLUSIONS: Patients with bioprostheses in the RVOT position after the Ross procedure showed a significantly higher risk of reintervention or pulmonary valve dysfunction. The main problem, early development of a stricture at the proximal suture line, has to be solved to achieve satisfactory bioprosthetic function in the RVOT.
No takes yet. Share an insight, caveat, or question.
Miskovic et al. (2012) conducted a cohort in Right ventricular outflow tract replacement in Ross procedures (n=186). Stentless bioprostheses (Medtronic Freestyle) vs. Homograft was evaluated on Incidence of reintervention owing to dysfunction of the RVOT replacement (p=0.007). Stentless bioprostheses for RVOT replacement after the Ross procedure had a higher incidence of reintervention compared to homografts.
Synapse has enriched 10 related papers. Consider them for comparative context: